NARINFLA expands 3F lifting ampoule overseas

ROSEROAD Co., Ltd. is expanding NARINFLA’s 3F Lifting Booster Ampoule into overseas markets as demand grows for simpler, ingredient-focused skincare and post-procedure home care. The product combines three growth factors and 12 peptides, and the brand says third-party testing and clinic adoption are helping drive momentum.

Why it matters: - The overseas push targets consumers looking for simpler routines and more ingredient-focused skincare. - NARINFLA is positioning the ampoule for the growing global interest in slow aging and post-procedure home care. - The product is designed to cover several skincare steps in one formula, which may appeal to users who want fewer products after aesthetic treatments.

What happened: - ROSEROAD Co., Ltd. is expanding NARINFLA’s "3F Lifting Booster Ampoule" into overseas markets. - The launch comes from South Korea, where NARINFLA is the skincare brand operated by ROSEROAD. - The company introduced the ampoule as a post-procedure home-care product built around a simplified routine. - A company spokesperson said the product was developed around the idea that home care after procedures matters as much as the treatment itself.

The details: - The ampoule combines three growth factors: EGF, FGF and IGF. - The formula also includes 12 peptides. - ROSEROAD says the product was developed over four years. - The formulation is aimed at a firmer-looking skincare routine and at supporting skin that can be sensitive or stressed after procedures. - The brand says DermaTest, the German third-party skin-compatibility evaluator, gave NARINFLA its top rating of "Excellent." - That rating measures low irritation potential and does not guarantee product performance. - Since launch, customer feedback on social media has helped broaden sales. - The company says 19 consecutive production batches have sold out. - NARINFLA is now sold at some dermatology clinics and professional skincare salons, including locations in Seoul’s Gangnam and Myeongdong districts.

Between the lines: - The brand is leaning on clinical-style positioning rather than mass-market beauty messaging. - Third-party testing and clinic distribution can help build trust for products aimed at sensitive skin and post-treatment care. - The emphasis on fewer steps reflects a broader shift toward minimal routines and ingredient-led skincare.

What's next: - ROSEROAD is expected to keep expanding NARINFLA’s overseas presence. - The brand is also likely to deepen ties with dermatology clinics and professional salons as it grows. - Consumers considering new skincare products should patch test first, use sunscreen daily and consult a dermatologist or other specialist for skin concerns.

The bottom line: - NARINFLA is taking a clinic-adjacent, ingredient-first skincare product global at a time when consumers want simpler routines and post-procedure care they can use at home.